Enhertu is a combination of a chemotherapy drug and targeted therapy. This type of therapy differs from immunotherapy. Doctors prescribe Enhertu for certain types of breast, lung, and other ...

Get Instant Summarized Text (Gist) Trastuzumab deruxtecan, known as Enhertu, has been approved in the UK for treating advanced HER2-positive cancers that are inoperable or have metastasized. This ...

Enhertu (fam-trastuzumab deruxtecan-nxki*) is a prescription drug used to treat certain kinds of cancer, including breast cancer. Enhertu is given by intravenous infusion (an injection into a vein ...

AstraZeneca and Daiichi Sankyo are preparing regulatory filings that could make their HER2-directed antibody-drug conjugate (ADC) Enhertu an option for previously untreated breast cancer for the ...

How Do I Use Enhertu for Breast Cancer? Doses of Enhertu are given as an IV through a blood vessel in your arm over a period of time. Your dose will be given by a health care provider every 3 ...

AstraZeneca and Daiichi Sankyo were clearly excited by data from a trial pitting their HER2 antibody-drug conjugate (ADC) Enhertu against Roche's rival Kadcyla when they reported top-line results ...

In the HER2-low population, treatment with trastuzumab deruxtecan reduced the risk of disease progression or death by 38% compared with chemotherapy. The Food and Drug Administration (FDA) has ...

Enhertu (trastuzumab deruxtecan), a HER2-targeting antibody-drug conjugate (ADC) bearing a deruxtecan (TOP1 inhibitor) warhead, was developed by Japanese pharmaceutical company Daichi Sankyo. A ...

Enhertu is part of a newer type of cancer treatment called antibody-drug conjugates (ADC). It works like a delivery system for medicine, even a "biologic missile." Imagine you're trying to deliver ...